Sobi publishes report for the first quarter 2021
Swedish Orphan Biovitrum AB (publ) (Sobi™) today announces its results for the first quarter 2021. Total revenue amounted to SEK 3,661 M, a decrease of 13 per cent at CER compared with the same period 2020. EBITA was SEK 1,484 M, resulting in an EBITA margin of 41 per cent. January – March · Total revenue of SEK 3,661 M (4,639), -21 per cent and -13 per cent at CER · EBITA[1 ]was SEK 1,484 M (2,173), with an EBITA margin[1] of 41 per cent (47) · Earnings per share (EPS) before dilution of SEK 2.36 (4.02) · Haematology sales were SEK 1,877 M (2,394),